Free tool
FAERS Monitor: Methotrexate
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 214121 or its brand name (Methotrexate, Methotrexate). Reports on generic versions are filed under their own applications.
Reports
487,627
Serious
358,960
74% of reports
Hospitalization
134,459
Death reported
38,300
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective93,085
- rheumatoid arthritis42,801
- arthralgia40,718
- off label use40,573
- pain39,635
- fatigue33,027
- nausea28,920
- joint swelling24,995
- drug intolerance24,515
- condition aggravated23,993
- headache23,450
- rash22,590
- diarrhoea20,904
- pain in extremity20,026
- drug hypersensitivity19,718
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 5,891 |
| 2005 | 5,584 |
| 2006 | 5,149 |
| 2007 | 8,029 |
| 2008 | 9,257 |
| 2009 | 9,418 |
| 2010 | 9,834 |
| 2011 | 10,985 |
| 2012 | 15,617 |
| 2013 | 17,734 |
| 2014 | 17,445 |
| 2015 | 21,279 |
| 2016 | 25,472 |
| 2017 | 32,187 |
| 2018 | 43,779 |
| 2019 | 40,975 |
| 2020 | 46,026 |
| 2021 | 30,926 |
| 2022 | 34,807 |
| 2023 | 32,370 |
| 2024 | 27,844 |
| 2025 | 23,597 |
| 2026 | 13,413 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,566,532 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| rheumatoid arthritisSignal | 42,801 | 25.5 | 25.2 | 630,952 |
| drug intoleranceSignal | 24,515 | 14.3 | 14.1 | 227,840 |
| joint swellingSignal | 24,995 | 11.0 | 10.9 | 181,256 |
| drug hypersensitivitySignal | 19,718 | 4.8 | 4.7 | 53,423 |
| arthralgiaSignal | 40,718 | 4.6 | 4.5 | 104,639 |
| condition aggravatedSignal | 23,993 | 3.6 | 3.6 | 42,307 |
| drug ineffectiveSignal | 93,085 | 3.2 | 3.2 | 139,758 |
| pain in extremitySignal | 20,026 | 3.1 | 3.0 | 26,460 |
| painSignal | 39,635 | 2.9 | 2.9 | 47,745 |
| rashSignal | 22,590 | 2.3 | 2.3 | 16,120 |
| off label useSignal | 40,573 | 2.0 | 2.0 | 21,623 |
| fatigue | 33,027 | 1.9 | 1.8 | 13,210 |
| headache | 23,450 | 1.6 | 1.6 | 5,768 |
| nausea | 28,920 | 1.6 | 1.6 | 6,477 |
| diarrhoea | 20,904 | 1.4 | 1.4 | 2,488 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.